Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)

NCT00528398 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00528398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
September 30, 1994
Completion date
December 31, 2015
Enrollment
111 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia